BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

 BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots:

  • MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory, and sales milestone along with royalties on future sales
  • MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain an exclusive WW license to develop and commercialize ETBs directed to each selected target
  • Following the exercise of the option, BMS would be solely responsible for developing and commercializing the licensed ETBs. The companies will utilize MTEM’s next-generation ETB platform for specific oncology targets

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Molecular Templates

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post